Key Takeaways
- Strong quarter, margin-led beat: EBITDA margin hit 17.5%, well above the ~16.5% full-year guide, driven by a favorable US product mix and raw material softening, though management explicitly warns this level is not sustainable.
- International business crosses ₹1,000 Cr again: US volume growth and reduced pricing deflation, plus strength in Chile, Europe, Kazakhstan and the Philippines, powered the second consecutive quarter above the milestone.
- Domestic recovery is tentative: A sluggish trend from Q1 persisted on delayed monsoons, with a noticeable pickup only in September; chronic therapies continue to outgrow the market while acute and trade generics lag.
- Gross margin guidance held, with a caveat: The 59.5% annual target is reaffirmed, but the US product mix that lifted Q2 may not repeat, and management asks investors to treat it as a potential one-off.
- What to watch next quarter: Whether the September domestic upturn sustains through H2, the pace of ANDA filings after a slow H1, and any resolution on Dabigatran's API supply chain bottleneck.
Margin Performance & Sustainability
- Q2 EBITDA margin surged to 17.5%: The jump was fueled by a better US product mix, softening API prices, and lower employee costs from internal efficiency programs across plants and R&D.
- US gross margin improvement is fragile: Higher-margin products contributed disproportionately to sales this quarter, but management cautions the same mix is unlikely to persist in coming quarters and suggests investors view it as a one-off.
- Raw material tailwind is real but incomplete: Most major API prices have softened, though anti-infective inputs tied to Pen G remain elevated at $28–$30 versus a pre-COVID baseline of $8–$10.
- Employee cost reduction is structural but plateauing: Manpower optimization in plants and R&D drove costs lower both sequentially and YoY; the savings are sustainable, but management does not expect the line item to keep falling quarter after quarter.
- Cost-cutting program near target: A corporate-wide efficiency drive spanning US operations, R&D, and plants serving both US and domestic markets is close to achieving its goal, though management disputes any single quantified figure was ever set for the US alone.
Sandeep Singh: "I think forget the quarter; quarter is great but this is not sustainable on an annual basis. I think we will be close to 16.5 for this year, year ending."
US Business: Pricing, Mix & Pipeline
- Price deflation has eased materially: US pricing erosion has moderated to roughly 5%–6% from low double digits earlier, and management expects prices have either bottomed out or will continue declining at a mid-single-digit rate.
- Volume and seasonality drove the top line: Lower price deflation combined with a low base in H1 last year, new product launches, and an extended flu season that sustained anti-infective demand through summer months.
- Dabigatran launch is live but supply-constrained: Alkem is one of only two generics approved, yet a primary API source is not supplying and a secondary source awaits FDA approval, leaving the product with negligible sales this quarter.
- Suprep remains in regulatory limbo: The product is pending with the US FDA, and management offers no timeline for approval or launch.
- Denosumab is a 2026 story: The biosimilar is in clinical stages; Alkem is open to either commercializing in-house or partnering, with a late-2026 target for the US market.
- Full-year US outlook: Management expects high single-digit dollar growth for FY24 over FY23, supported by new launches and a more benign pricing environment.
Dr Vikas Gupta: "So, just to add to it, Nithya, the mix that we have in US, we are not sure whether the same mix will continue in the coming quarters as well. So, that you may still, if you want to qualify as a one-off, you may look at that."
Domestic Business: Chronic Strength, Acute Weakness
- Q2 started sluggish, ended better: Sporadic and delayed monsoons extended the lackluster Q1 trend, but a noticeable improvement took hold in September, and October was described as fairly in line with the market.
- Chronic therapies are the growth engine: Cardiac, anti-diabetic, and CNS segments all grew strong double digits, with Alkem advancing two ranks in anti-diabetic and one rank each in neuro, CNS, and cardiac therapy.
- Strategy is brand concentration, not field force expansion: Chronic growth is being driven by focusing resources on a few key brands rather than adding sales representatives; the ~10% field force expansion is complete, and the game plan now is increasing productivity.
- Trade generics and anti-infectives underperformed: Seasonality and geographic concentration in sluggish markets dragged the trade generic franchise, while acute therapies faced headwinds from the delayed monsoon.
- Full-year domestic expectation: Management is targeting higher single-digit growth on an annualized basis, implying an acceleration from the mid-single-digit trend seen so far.
Dr Vikas Gupta: "So, chronic, we have a clear strategy that we have in place and that's one of the most important areas and levers of growth for domestic business in India."
Enzene Bioscience: Early-Stage Investment Thesis
- Growth is the priority, not profit: Management is explicit that Enzene should not be expected to generate significant profit for the next 3–4 years; the focus is on building the business.
- Sharp sequential sales jump: The QoQ revenue spike was driven by new product launches and B2B partnerships with other Indian pharma companies; six products are now launched, with a seventh (ranibizumab, a Lucentis generic) approved and preparing for takeoff.
- Breakeven timeline is near but not the goal: Next year could be closer to breakeven, but management reiterates that growth takes precedence over profitability at this stage.
Sandeep Singh: "I think this is very early stage for biotech. So, honestly for the next 3-4 years, we really should not expect it to like to generate a lot of profit even though even if they breakeven but I think growth is a priority here."
R&D, Filings & Capital Allocation
- ANDA filings are back-ended: H1 saw only five ANDAs filed, but management targets 8–9 for the full year, with filings weighted toward H2 and focused on products and markets where the payback on entry is more profitable and less exposed to price erosion.
- R&D spend is shifting, not shrinking: H1 spend was lower due to fewer ANDAs; some small-molecule R&D has been cut, with resources reallocated toward more complex products including clinical trials for Denosumab in the US.
- M&A appetite is warming slowly: Management is slightly more open to M&A than in recent quarters, with chronic therapies as the highest priority and OTC or consumer as a possible secondary segment. No deal is expected in the next few months, and the company will not take on debt for a large acquisition given its cash position.
- ROW markets are a steady growth layer: International markets beyond the US delivered good performance in Chile, Europe, Kazakhstan, and the Philippines; management views this growth as sustainable and aims to add one or two new markets each year.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | ~16.5% for full year FY24; Q2's 17.5% not sustainable annually | FY24 |
| Gross margin | 59%–59.5% on annualized basis; confident of matching 59.5% | FY24 |
| US dollar revenue growth | High single-digit growth in dollar terms | FY24 over FY23 |
| ANDA filings | 8–9 filings, back-ended in H2 | FY24 |
| Tax rate | Revised to 12%–15% from ~18% | FY24 |
| Sikkim tax benefit | Benefit lasts until March 2026; no fixed benefit from April 2026 onward | Through Mar 2026 |
| Denosumab US commercialization | Late 2026 target | Late 2026 |
| Enzene Bioscience profitability | Do not expect significant profit; growth is the priority | Next 3–4 years |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue from operations | Not explicitly stated for Q2 FY24 in transcript or scratchpad |
| EBITDA margin | 21.7% |
| Net profit after tax | ₹620 cr |
| Cash generated from operations | ₹470 cr during the quarter |
| Net cash position | ₹2,900 cr as of September 30, 2023 |
| Gross margin | ~61% (per an analyst's math) |
| International business revenue | Surpassed ₹1,000 cr for the second consecutive quarter |
| US pricing deflation | ~5% to 6% (big single digit) |
| ANDA approvals | 4 approvals including 1 tentative approval during the quarter |
| India field force | ~12,000 first-line MRs |
| Trade generic business contribution | ~20% to 21% of domestic business, growth of 6% to 7% |
| Enzene Bioscience cost | ₹80 cr in Q2 FY24, profitability slightly negative but close to breakeven |
| Tax rate guidance | Revised to 12% to 15% for FY24 from earlier ~18% |
| Full year FY24 EBITDA margin guidance | ~16.5% |
| Full year FY24 gross margin guidance | Maintained at 59% to 59.5% on an annualized basis |